Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.

Novo Nordisk’s blockbuster weight-loss drug Wegovy is now available for use in China, the company confirmed to AFP on Tuesday, as the Asian nation battles ...

The move intensifies the competition with Eli Lilly, which secured approval for its weight loss drug in China in July but has ...

Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...

Lilly is aiming to strengthen its position as a leader in the obesity treatment market, which is expected to hit $150 billion ...

European mega-caps trail US 'Magnificent 7' amid lack of AI gains, while also facing China’s slowdown and rising geopolitical ...

Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

Healthcare is an active sector for M&A, with deals such as Johnson & Johnson's acquisition of heart device business Shockwave ...

Novo Nordisk rose after the Danish giant launched its Wegovy weight-loss product in China. Merck reported promising trial results for a new, easier-to-administer formulation of its blockbuster cancer ...

This investor's weighing up a couple of world-class companies for his Stocks and Shares ISA after the US election sparked a sell-off.

The number of public electric vehicle (EV) charging points in Denmark has grown by over 70 percent in the past year, according to new data from Mobility Denmark. In October 2024, there were 27,298 ...